Alternatively, non-endothelial FGFR signaling may contribute to cancer growth and choosing drugs with moderate VEGFR2 and FGFR1/2 inhibitory properties still should be considered and may be more efficacious and less toxic than strongly inhibiting both pathways. The gene discussed is KDR; the disease is cancer.